Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Agomelatine→

Agomelatine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
138112-76-2
Molecular formula
C15H17NO2
Molecular weight
243.3 g/mol
Drug class
Melatonergic antidepressant
Mechanism of action
Acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C receptors; it can resynchronise circadian rhythms.
Indications / reported uses
  • Treatment of major depressive episodes in adults

Sources: UK SmPC (eMC)

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Agomelatine Environmental Risk Assessment (ERA) (the Agomelatine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.